Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 321:1364-13711989., , 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
Selegiline as an Adjunct to Conventional Levodopa Therapy in Parkinson's Disease
Arch Neurol 46:1280-1283, Elizan,T.S.,et al, 1989
Swallowing Abnormalities and Their Response to Treatment in Parkinson's Disease
Neurol 39:1309-1314, Bushman,M.,et al, 1989
Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989
Gerstmann-Straussler-Scheinker Disease, I, Extending the Clinical Spectrum
Neurol 39:1446-1452, Farlow,M.R.,et al, 1989
Cyanide-Induced Parkinsonism:Clinical, MRI, and 6-Fluorodopa PET Studies
Neurol 39:142-144, Rosenberg,N.L.,et al, 1989
Bromocriptine in Parkinson's Disease:A Double-Blind Study Comparing"Low-Slow"and"High-Fast"in de Novo Patients
UK Bromocriptine Res Group, JNNP 52:77-821989., , 1989
Acute Postoperative Confusion and Hallucinations in Parkinson Disease
Ann Int Med 111:218-222, Golden,W.E.,et al, 1989
Clozapine in the Treatment of Psychosis in Parkinson's Disease
Neurol 39:1219-1221, Friedman,J.H.&Lannon,M.C., 1989
Induction of Parkinsonism by Intraventricular Bethanechol in a Patient with Alzheimer's Disease
Neurol 39:1265, Fox,J.H.,et al, 1989
Parkinsonism and Amiodarone Therapy
Ann Neurol 25:630-632, Werner,E.G.&Olanow,C.W., 1989
Bilateral Ballism in Multiple Sclerosis
Neurol 39:1641-1642, Masucci,E.F.,et al, 1989
Metoclopramide-Induced Movement Disorders
Arch Int Med 149:2486-2492, Miller,L.G.&Jankovic,J., 1989
Mild Parkinsonism in Persons Exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
Neurol 39:1483-1487, Tetrud,J.W.,et al, 1989
Hemiballism-Hemichorea, Clinical and Pharmacologic Findings in 21 Patients
Arch Neurol 46:862-867, Dewey,R.B.&Jankovic,J., 1989
Sleep Abnormalities in Progressive Supranuclear Palsy
Ann Neurol 25:577-581, Aldrich,M.S.,et al, 1989
Autologous Adrenal Medullary Transplant in Progressive Supranuclear Palsy
Neurol 39:1066-1068, Koller,W.C.,et al, 1989
MR Imaging in Progressive Suupranuclear Palsy and Shy-Drager Syndrome
J Comput Assist Tomogr 13:555-560, Savoiardo,M.,et al, 1989
Diltiazem-Induced Parkinsonism
Am J Med 87:95-96, Dick,R.S.&Barold,S.S., 1989
Risk Factors for Recurrent Nonsyncopal Falls, A Prospective Study
JAMA 261:2663-2668, Nevitt,M.C.,et al, 1989
Implantation of Tissue Into the Brain, An Immunologic Perspective
JAMA 261:2674-2676, Gill,T.J.&Lund,R.D., 1989
Rising Mortality From Motoneuron Disease in the USA, 1962-84
Lancet 1:710-712, Lilienfeld,D.E.,et al, 1989
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Cognitive Impairments Associated with Early Parkinson's Disease
Neurol 39:557-561, Levin,B.E.,et al, 1989
Clinical and Pathological Aspects of Parkinsonism in Alzheimer's Disease, A Role for Extranigral Factors?
Arch Neurol 46:651-657, Morris,J.C.,et al, 1989
Neuropathological Distinction Between Parkinson's Dementia and Parkinson's Plus Alzheimer's Disease
Ann Neurol 26:309-320, delaMonte,S.M.,et al, 1989
Long-Term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease
Neurol 39:1109-1111, Golbe,L.I.,et al, 1989
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Science 245:519-522, Tetrud,J.W.&Langston,W., 1989
Agonist Substitution in Advanced Parkinson's Disease
Neurol 39:1121-1122, Goetz,C.G.,et al, 1989
Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989
Human Fetal Dopamine Neurons Grafted Into the Striatum in Two Patients with Severe Parkinson's 6-Mo Follow-up
Arch Neurol 46:615-631, Lindvall,O.,et al, 1989
The Ethical Use of Human Fetal Tissue in Medicine
NEJM 320:1093-1096, Greely,H.T.,et al, 1989
The Politics of Transplantation of Human Fetal Tissue
NEJM 320:1079-1082, Annas,G.J.&Elias,S., 1989
Postmortem Analysis of Adrenal-Medulla-to-Caudate Autograft in a Patient with Parkinson's Disease
Ann Neurol 25:607-614, Hurtig,H.,et al, 1989
Adrenal Medullary Transplantation to the Caudate Nucleus in Parkinson's Disease, Initial Results in 18 Patients
Arch Neurol 46:487-491, Allen,G.S.,et al, 1989
Adrenal Medullary Autografts in Patients with Parkinson's Disease
NEJM 321:324-327, Tanner,C.M.,et al, 1989
Clinical, Biochem, & Neuropath of Transplantation of Adrenal Medulla to Caudate Nucleus for Parkinson's
Neurol 39:1227-1234, Jankovic,J.,et al, 1989
Amount and Distribution of Dietary Protein Affects Clinical Response to Levodopa in Parkinson's Disease
Neurol 39:552-556, Carter,J.H., 1989
Influence of Fluctuations of Plasma Large Neutral Amino Acids with Normal Diets on the Clinical Response to Levodopa
JNNP 52:481-487, Nutt,J.G.,et al, 1989
The Effect of Dietary Protein on the Efficacy of L-Dopa:A Double-Blind Study
Neurol 39:549-552, Tsui,J.K.,et al, 1989
Accuracy of Self-Reported Disability in Patients with Parkinsonism
Arch Neurol 46:955-959, Brown,R.G.,et al, 1989
Psychiatric Aspects of Parkinson's Disease, Dementia, Depression, and Rarely Psychosis
BMJ 299:3-4, Baldwin,R.C.&Byrne,E.J., 1989
Effect of Age at Onset on Progression and Mortality in Parkinson's Disease
Neurol 39:1187-1190, Diamond,S.G.,et al, 1989
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989
The Olfactory and Cognitive Deficits of Parkinson's Disease:Evidence for Independence
Ann Neurol 25:166-171, Doty,R.L.,et al, 1989